<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01961414</url>
  </required_header>
  <id_info>
    <org_study_id>VGFT-OD-1319</org_study_id>
    <nct_id>NCT01961414</nct_id>
  </id_info>
  <brief_title>Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910</brief_title>
  <acronym>RANGE</acronym>
  <official_title>Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palmetto Retina Center, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Palmetto Retina Center, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if a &quot;Treat and Extend&quot; regimen&#xD;
      (increasing the time between visits when the disease is stable and not getting worse) of&#xD;
      aflibercept 2.0mg injections inside the eye for treating patients with Wet Age-related&#xD;
      Macular Degeneration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After exiting VGFT-OD 0910, patients will be enrolled into RANGE, a longterm extension trial&#xD;
      evaluating the safety and efficacy of aflibercept IAI utilizing a &quot;treat and extend&quot; regimen.&#xD;
      Using pre-specified re-treatment criteria, treatment intervals will be variable with dosing&#xD;
      of the active treatment at least every 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Portion of patients who maintain vision (loss of &lt; or = 5 letters ETDRS BCVA) from baseline to Year 1.</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Exudative Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive aflibercept 2.0mg intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits</description>
    <arm_group_label>Aflibercept</arm_group_label>
    <other_name>Eylea 2.0mg, VEGF TRAP-EYE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous enrollment in 0910-extension study evaluating intravitreal aflibercept&#xD;
             injection (NCT 00964795) without early study discontinuation prior to sponsor early&#xD;
             termination.&#xD;
&#xD;
          -  Patients are enrolled within 90 days of site activation (all attempts will be made to&#xD;
             ensure IAI is given once exited from the 0910-extension and prior to enrollment).&#xD;
&#xD;
          -  Willing and able to comply with clinical visits and study related procedures.&#xD;
&#xD;
          -  Provide signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with verteporfin, or external-beam radiation therapy, or&#xD;
             transpupillary thermotherapy in the study eye&#xD;
&#xD;
          -  Previous subfoveal focal laser photocoagulation involving the foveal center in the&#xD;
             study eye&#xD;
&#xD;
          -  History of vitrectomy, submacular surgery, or other surgical intervention for AMD in&#xD;
             the study eye&#xD;
&#xD;
          -  Any concurrent intraocular condition in the study eye (e.g. diabetic retinopathy or&#xD;
             glaucoma) that, in the opinion of the investigator, could either&#xD;
&#xD;
               -  require medical or surgical intervention during the study period to prevent or&#xD;
                  treat visual loss that might result from that condition, or&#xD;
&#xD;
               -  if allowed to progress untreated, could likely contribute to loss of at least 2&#xD;
                  Snellen equivalent lines of best corrected visual acuity over the study period&#xD;
&#xD;
          -  Active intraocular inflammation (grade trace or above) in the study eye, or history of&#xD;
             idiopathic or autoimmune-associated uveitis in either eye&#xD;
&#xD;
          -  Current vitreous hemorrhage in the study eye&#xD;
&#xD;
          -  History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the&#xD;
             study eye&#xD;
&#xD;
          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either&#xD;
             eye&#xD;
&#xD;
          -  Aphakia, ACIOL, or unstable PCIOL&#xD;
&#xD;
          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure â‰¥30 mmHg&#xD;
             despite treatment with anti-glaucoma medication)&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Sexually active men* or women of childbearing potential** who are unwilling to&#xD;
             practice adequate contraception during the study (adequate contraceptive measures&#xD;
             include stable use of oral contraceptives or other prescription pharmaceutical&#xD;
             contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device&#xD;
             [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or&#xD;
             jelly, or diaphragm plus contraceptive sponge, foam, or jelly)&#xD;
&#xD;
               -  Contraception is not required for men with documented vasectomy.&#xD;
&#xD;
                    -  Postmenopausal women must be amenorrheic for at least 12 months in order not&#xD;
                       to be considered of child bearing potential. Pregnancy testing and&#xD;
                       contraception are not required for women with documented hysterectomy or&#xD;
                       tubal ligation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William L. Clark, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Palmetto Retina Center, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southeast Retina</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Surgical Associates</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Retina Center</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Retina</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 9, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2013</study_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exudative</keyword>
  <keyword>AMD</keyword>
  <keyword>Macular</keyword>
  <keyword>Degeneration</keyword>
  <keyword>Aflibercept</keyword>
  <keyword>Eylea</keyword>
  <keyword>Intravitreal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 30, 2018</submitted>
    <returned>September 25, 2018</returned>
    <submitted>March 19, 2019</submitted>
    <returned>April 12, 2019</returned>
    <submitted>November 12, 2019</submitted>
    <returned>December 3, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

